Vyant Bio Investor Relations Material
Latest events
Q3 2022
Vyant Bio
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Vyant Bio Inc
Access all reports
Vyant Bio, Inc. operates as a biotechnology drug discovery company. The company discovers, develops, and commercializes antimicrobial drugs to treat acute respiratory tract infections, including pneumonia and influenza.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
VYNT
Country
🇺🇸 United States